It is crucial, especially in the context of the introduction of novel immunotherapies (i.e., anti-II ligand lymphocyte activation gene-3 [LAG-3] [55,56], and tebentafusp [57,58]) which are being extensively investigated in clinical trials and showing promising results in melanoma patients. This evidence concerns the gene LAG3 and melanoma.